Obsessive-compulsive disorder and gut microbiota dysregulation

Medical Hypotheses

Volumn 82, Issue 2, 2014, Pages 163-166

  Rees, Jon C ^a  

^a NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT;

ANTIBIOTIC THERAPY; ARTICLE; AUTOIMMUNE DISEASE; COPING BEHAVIOR; DISEASE ASSOCIATION; DISEASE PREDISPOSITION; GROUP A STREPTOCOCCAL INFECTION; HYPOTHESIS; INTESTINE FLORA; OBSESSIVE COMPULSIVE DISORDER; PEDIATRIC AUTOIMMUNE NEUROPSYCHIATRIC DISORDERS ASSOCIATED WITH STREPTOCOCCAL INFECTION; PREGNANCY; STREPTOCOCCUS INFECTION; STRESS;

ANTI-BACTERIAL AGENTS; ANXIETY; CENTRAL NERVOUS SYSTEM; FECES; FEMALE; HUMANS; INTESTINES; MICROBIOTA; MODELS, THEORETICAL; OBSESSIVE-COMPULSIVE DISORDER; PREGNANCY;

EID: 84892366170     PISSN: 03069877     EISSN: 15322777     Source Type: Journal    
DOI: 10.1016/j.mehy.2013.11.026     Document Type: Article

References (71)

1. FDA issues public health advisory on cautions for use of antidepressants in adults and children.
2. Kugler B.B., Lewin A.B., Phares V., Geffken G.R., Murphy T.K., Storch E.A. Quality of life in obsessive-compulsive disorder: the role of mediating variables. Psychiatry Res 2013, 206:43-49.
3. Eisen J.L., Mancebo M.A., Pinto A., Coles M.E., Pagano M.E., Stout R., Rasmussen S.A., et al. Impact of obsessive-compulsive disorder on quality of life. Compr Psychiatry 2006, 47:270-275.
4. Stengler-Wenzke K., Kroll M., Matschinger H., Angermeyer M.C. Quality of life of relatives of patients with obsessive-compulsive disorder. Compr Psychiatry 2006, 47:523-527.
5. Abudy A., Juven-Wetzler A., Zohar J. Pharmacological management of treatment-resistant obsessive-compulsive disorder. CNS Drugs 2011, 25:585-596. [510.2165/11587860-000000000-000000000].
6. Goodman W., McDougle C., Price L. Pharmacotherapy of obsessive compulsive disorder. J Clin Psychiatry 1992, 53(Suppl.):29-37.
7. Jenike M.A., Rauch S.L. Managing the patient with treatment-resistant obsessive compulsive disorder: current strategies. J Clin Psychiatry 1994, 55:11-17.
8. McDougle C., Goodman W., Leckman J.F., Barr L., Heninger G., Price L. The efficacy of fluvoxamine in obsessive-compulsive disorder: effects of comorbid chronic tic disorder. J Clin Psychopharmacol 1993, 13:354-358.
9. McDougle C., Goodman W., Leckman J.F., Price L. The psychopharmacology of obsessive compulsive disorder. Implications for treatment and pathogenesis. Psychiatr Clin North Am 1993, 16:749-766.
10. Piccinelli M., Pini S., Bellantuono C., Wilkinson G. Efficacy of drug treatment in obsessive-compulsive disorder. A meta-analytic review. Br J Psychiatry 1995, 166:424-443.
11. Pigott T., Seay S. A review of the efficacy of selective serotonin reuptake inhibitors in obsessive-compulsive disorder. J Clin Psychiatry 1999, 60:101-106.
12. Fineberg N.A., Reghunandanan S., Brown A., Pampaloni I. Pharmacotherapy of obsessive-compulsive disorder: evidence-based treatment and beyond. Aust NZ J Psychiatry 2013, 47:121-141.
13. de Kloet E.R., Joels M., Holsboer F. Stress and the brain: from adaptation to disease. Nat Rev Neurosci 2005, 6:463-475.
14. Altemus M., Pigott T., Kalogeras K.T., Demitrack M., Dubbert B., Murphy D.L., Gold P.W., et al. Abnormalities in the regulation of vasopressin and corticotropin releasing factor secretion in obsessive-compulsive disorder. Arch Gen Psychiatry 1992, 49:9-20.
15. Catapano F., Monteleone P., Fuschino A., Maj M., Kemali D. Melatonin and cortisol secretion in patients with primary obsessive-compulsive disorder. Psychiatry Res 1992, 44:217-225.
16. Monteleone P., Catapano F., Tortorella A., Maj M. Cortisol response to d-fenfluramine in patients with obsessive-compulsive disorder and in healthy subjects: evidence for a gender-related effect. Neuropsychobiology 1997, 36:8-12.
17. Kluge M., Schüssler P., Künzel H.E., Dresler M., Yassouridis A., Steiger A. Increased nocturnal secretion of ACTH and cortisol in obsessive compulsive disorder. J Psychiatr Res 2007, 41:928-933.
18. Lindsay J.R., Nieman L.K. The hypothalamic-pituitary-adrenal axis in pregnancy: challenges in disease detection and treatment. Endocr Rev 2005, 26:775-799.
19. Abramowitz J.S., Schwartz S.A., Moore K.M., Luenzmann K.R. Obsessive-compulsive symptoms in pregnancy and the puerperium: a review of the literature. J Anxiety Disord 2003, 17:461-478.
20. Andersson L., Sundström-Poromaa I., Bixo M., Wulff M., Bondestam K., Åström M. Point prevalence of psychiatric disorders during the second trimester of pregnancy: a population-based study. Am J Obstet Gynecol 2003, 189:148-154.
21. Maina G., Albert U., Bogetto F., Vaschetto P., Ravizza L. Recent life events and obsessive-compulsive disorder (OCD): the role of pregnancy/delivery. Psychiatry Res 1999, 89:49-58.
22. Uguz F., Gezginc K., Zeytinci I.E., et al. Obsessive-compulsive disorder in pregnant women during the third trimester of pregnancy. Compr Psychiatry 2007, 48:441-445.
23. Uguz F., Kaya V., Gezginc K., Kayhan F., Cicek E. Clinical correlates of worsening in obsessive-compulsive symptoms during pregnancy. Gen Hosp Psychiatry 2011, 33:197-199.
24. Williams K., Koran L.M. Obsessive-compulsive disorder in pregnancy, the puerperium and the premenstruum. J Clin Psychiatry 1997, 58:330-334.
25. Forray A., Focseneanu M., Pittman B., McDougle C., Epperson C. Onset and exacerbation of obsessive-compulsive disorder in pregnancy and the postpartum period. J Clin Psychiatry 2010, 71:1061-1068.
26. Neziroglu G., Anemone R., Yaryura-Tobias J. Onset of obsessive-compulsive disorder in pregnancy. Am J Psychiatry 1992, 149:947-950.
27. Roth M.K., Bingham B., Shah A., et al. Effects of chronic plus acute prolonged stress on measures of coping style, anxiety, and evoked HPA-axis reactivity. Neuropharmacology 2012, 63:1118-1126.
28. Frodl T., O'Keane V. How does the brain deal with cumulative stress? A review with focus on developmental stress, HPA axis function and hippocampal structure in humans. Neurobiol Dis 2013, 52:24-37.
29. de Silva P., Marks M. The role of traumatic experiences in the genesis of obsessive-compulsive disorder. Behav Res Ther 1999, 37:941-951.
30. Rosso G., Albert U., Asinari G.F., Bogetto F., Maina G. Stressful life events and obsessive-compulsive disorder: clinical features and symptom dimensions. Psychiatry Res 2012, 197:259-264.
31. Millet B., Kochman F., Gallarda T., et al. Phenomenological and comorbid features associated in obsessive-compulsive disorder: influence of age of onset. J Affect Disord 2004, 79:241-246.
32. Gill S.R., Pop M., DeBoy R.T., et al. Metagenomic analysis of the human distal gut microbiome. Science 2006, 312:1355-1359.
33. Clemente Jose C., Ursell Luke K., Parfrey Laura W., Knight R. The impact of the gut microbiota on human health: an integrative view. Cell 2012, 148:1258-1270.
34. Hooper L.V., Macpherson A.J. Immune adaptations that maintain homeostasis with the intestinal microbiota. Nat Rev Immunol 2010, 10:159-169.
35. Kamada N., Seo S.-U., Chen G.Y., Nunez G. Role of the gut microbiota in immunity and inflammatory disease. Nat Rev Immunol 2013, 13:321-335.
36. Renz H., Brandtzaeg P., Hornef M. The impact of perinatal immune development on mucosal homeostasis and chronic inflammation. Nat Rev Immunol 2012, 12:9-23.
37. Stecher B., Hardt W.-D. Mechanisms controlling pathogen colonization of the gut. Curr Opin Microbiol 2011, 14:82-91.
38. De Filippo C., Cavalieri D., Di Paola M., et al. Impact of diet in shaping gut microbiota revealed by a comparative study in children from Europe and rural Africa. Proc Natl Acad Sci 2010.
39. Pflughoeft K.J., Versalovic J. Human microbiome in health and disease. Annu Rev Pathol Mech Dis 2012, 7:99-122.
40. Zimomra Z.R., Porterfield V.M., Camp R.M., Johnson J.D. Time-dependent mediators of HPA axis activation following live Escherichia coli. Am J Physiol Regul Integr Comp Physiol 2011, 301:R1648-R1657.
41. Dinan T.G., Cryan J.F. Regulation of the stress response by the gut microbiota: implications for psychoneuroendocrinology. Psychoneuroendocrinology 2012, 37:1369-1378.
42. Dinan TG, Stanton C, Cryan JF. Psychobiotics: a novel class of psychotropic, Biol Psychiatry, 2013.
43. Tannock G.W., Savage D. Influences of dietary and environmental stress on microbial populations in the murine gastrointestinal tract. Infect Immun 1974, 9:591-598.
44. Bailey M.T., Dowd S.E., Galley J.D., Hufnagle A.R., Allen R.G., Lyte M. Exposure to a social stressor alters the structure of the intestinal microbiota: implications for stressor-induced immunomodulation. Brain Behav Immun 2011, 25:397-407.
45. Rashid M.-U., Weintraub A., Nord C.E. Effect of new antimicrobial agents on the ecological balance of human microflora. Anaerobe 2012, 18:249-253.
46. Sullivan Å., Edlund C., Nord C.E. Effect of antimicrobial agents on the ecological balance of human microflora. Lancet Infect Dis 2001, 1:101-114.
47. Beaugerie L., Petit J.-C. Antibiotic-associated diarrhoea. Best Pract Res Clin Gastroenterol 2004, 18:337-352.
48. Marra F., Lynd L., Coombes M., et al. Does antibiotic exposure during infancy lead to development of asthma?: a systematic review and metaanalysis. CHEST J 2006, 129:610-618.
49. Prioult G., Nagler-Anderson C. Mucosal immunity and allergic responses: lack of regulation and/or lack of microbial stimulation?. Immunol Rev 2005, 206:204-218.
50. Pimentel M., Chang C. Inflammation and microflora. Gastroenterol Clin North Am 2011, 40:69-85.
51. Jernberg C, Lofmark S, Edlund C, Jansson JK. Long-term ecological impacts of antibiotic administration on the human intestinal microbiota, ISME J 1 (2007); p. 56-66.
52. Löfmark S., Jernberg C., Billström H., Andersson D.I., Edlund C. Restored fitness leads to long-term persistence of resistant Bacteroides strains in the human intestine. Anaerobe 2008, 14:157-160.
53. Sjölund M., Wreiber K., Andersson D.I., Blaser M.J., Engstrand L. Long-term persistence of resistant Enterococcus species after antibiotics to eradicate Helicobacter pylori. Ann Intern Med 2003, 139:483-487.
54. Swedo S.E., Leonard H.L., Garvey M., et al. Pediatric autoimmune neuropsychiatric disorders associated with streptococcal infections: clinical description of the first 50 cases. Am J Psychiatry 1998, 155:264-271.
55. Gilbert D.L., Kurlan R. PANDAS: horse or zebra?. Neurology 2009, 73:1252-1253.
56. Martino D., Defazio G., Giovannoni G. The PANDAS subgroup of tic disorders and childhood-onset obsessive-compulsive disorder. J Psychosom Res 2009, 67:547-557.
57. Snider L.A., Swedo S.E. PANDAS: current status and directions for research. Mol Psychiatry 2004, 9:900-907.
58. Perlmutter S.J., Leitman S.F., Garvey M.A., et al. Therapeutic plasma exchange and intravenous immunoglobulin for obsessive-compulsive disorder and tic disorders in childhood. Lancet 1999, 354:1153-1158.
59. Yatsunenko T., Rey F.E., Manary M.J., et al. Human gut microbiome viewed across age and geography. Nature 2012, 486:222-227.
60. Forslund K., Sunagawa S., Kultima J.R., et al. Country-specific antibiotic use practices impact the human gut resistome. Genome Res 2013, 23:1163-1169.
61. Logan A.C., Katzman M. Major depressive disorder: probiotics may be an adjuvant therapy. Med Hypotheses 2005, 64:533-538.
62. Lyte M. Probiotics function mechanistically as delivery vehicles for neuroactive compounds: microbial endocrinology in the design and use of probiotics. BioEssays 2011, 33:574-581.
63. Barrett E., Ross R.P., O'Toole P.W., Fitzgerald G.F., Stanton C. Γ-Aminobutyric acid production by culturable bacteria from the human intestine. J Appl Microbiol 2012, 113:411-417.
64. Desbonnet L., Garrett L., Clarke G., Bienenstock J., Dinan T.G. The probiotic Bifidobacteria infantis: an assessment of potential antidepressant properties in the rat. J Psychiatr Res 2008, 43:164-174.
65. Bested A., Logan A., Selhub E. Intestinal microbiota, probiotics and mental health: from Metchnikoff to modern advances: part III - convergence toward clinical trials. Gut Pathog 2013, 5:4.
66. Septimus E.J., Owens R.C. Need and potential of antimicrobial stewardship in community hospitals. Clin Infect Dis 2011, 53:S8-S14.
67. Abou-Donia M.B., El-Masry E.M., Abdel-Rahman A.A., McLendon R.E., Schiffman S.S. Splenda alters gut microflora and increases intestinal P-glycoprotein and cytochrome P-450 in male rats. J Toxicol Environ Health A 2008, 71:1415-1429.
68. Schiffman S.S., Abou-Donia M.B. Sucralose revisited: rebuttal of two papers about Splenda safety. Regul Toxicol Pharmacol 2012, 63:505-508.
69. Brusick D., Borzelleca J.F., Gallo M., et al. Expert Panel report on a study of Splenda in male rats. Regul Toxicol Pharmacol 2009, 55:6-12.
70. Grotz V.L., Brusick D. Response to the letter to the editor by S. Schiffman and M. Abou-Donia: additional information to clarify the evidence of sucralose safety. Regul Toxicol Pharmacol 2012, 63:509-513.
71. Hildebrandt M.A., Hoffmann C., Sherrill-Mix S.A., et al. High-fat diet determines the composition of the murine gut microbiome independently of obesity. Gastroenterology 2009, 137:1716-1724. [e1712].